These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 3092288

  • 1. Dopamine control of aldosterone secretion in end-stage renal failure.
    García-Robles R, Ruilope L, Tovar J, de Villa LF, Miranda B, Prieto C, Parada J, Sancho J, Rodicio JL.
    Rev Esp Fisiol; 1986 Jun; 42(2):257-63. PubMed ID: 3092288
    [Abstract] [Full Text] [Related]

  • 2. Dopaminergic modulation of aldosterone secretion in the normal menstrual cycle.
    Garcia-Robles R, Ruilope LM, Tovar J, de Pablos P, Parada J, Hurtado A, Miranda B, Fernandez Vazquez G, Rodicio JL, Sancho J.
    J Clin Hypertens; 1987 Dec; 3(4):470-8. PubMed ID: 3134515
    [Abstract] [Full Text] [Related]

  • 3. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
    García-Robles R, Ruilope L, Mancheño E, Hurtado A, Alcázar JM, Varela C, de la Calle H, Rodicio JL, Sancho J.
    Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
    [Abstract] [Full Text] [Related]

  • 4. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T, Jungmann E, Althoff P, Schumm-Draeger PM, Usadel KH.
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [Abstract] [Full Text] [Related]

  • 5. Altered dopaminergic modulation of prolactin and aldosterone secretion in pseudohypoparathyroidism.
    Sowers JR, Brickman AS, Asp N, Tuck ML, Jasberg K, Magnone S.
    J Clin Endocrinol Metab; 1981 May; 52(5):914-8. PubMed ID: 7014587
    [Abstract] [Full Text] [Related]

  • 6. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
    Tresguerres JA, Esquifino AI.
    Acta Physiol Lat Am; 1983 May; 33(3):257-74. PubMed ID: 6424409
    [Abstract] [Full Text] [Related]

  • 7. [Role of renin-angiotensin-aldosterone system in pathogenesis of arterial hypertension in chronic renal failure].
    Lifshits NL, Kutyrina IM.
    Ter Arkh; 1999 May; 71(6):64-7. PubMed ID: 10420461
    [Abstract] [Full Text] [Related]

  • 8. Control of plasma aldosterone in terminal renal failure before and after nephrectomy and after renal transplantation.
    Vetter W, Záruba K, Armbruster H, Beckerhoff R, Uhlschmid G, Furrer J, Siegenthaler W.
    Clin Nephrol; 1976 Oct; 6(4):433-6. PubMed ID: 788978
    [Abstract] [Full Text] [Related]

  • 9. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
    Carey RM, Thorner MO, Ortt EM.
    J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
    [Abstract] [Full Text] [Related]

  • 10. Serum aldosterone response to metoclopramide in normal subjects and acromegalic patients.
    Zacharieva S, Stoeva I, Matrozov P, Andonova K.
    Exp Clin Endocrinol; 1990 Aug; 95(3):331-8. PubMed ID: 2245821
    [Abstract] [Full Text] [Related]

  • 11. Tonic dopaminergic suppression of plasma aldosterone.
    Noth RH, McCallum RW, Contino C, Havelick J.
    J Clin Endocrinol Metab; 1980 Jul; 51(1):64-9. PubMed ID: 7380993
    [Abstract] [Full Text] [Related]

  • 12. Influence of sodium homeostasis on dopaminergic modulation of aldosterone, renin, and prolactin secretion in man.
    Sowers JR, Glub MS, Eggena PH, Catania RA.
    J Clin Endocrinol Metab; 1982 Jan; 54(1):121-6. PubMed ID: 7033264
    [Abstract] [Full Text] [Related]

  • 13. Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.
    Sowers J, Catania R, Paris J, Tuck M.
    J Clin Endocrinol Metab; 1982 Mar; 54(3):510-6. PubMed ID: 7035482
    [Abstract] [Full Text] [Related]

  • 14. Role of prolactin and the renin-angiotensin system in mediating dopaminergic control of aldosterone secretion in the rat.
    Sowers JR, Golub M, Tuck M, Sowers DK.
    Clin Exp Hypertens (1978); 1981 Mar; 3(1):1-14. PubMed ID: 7472089
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive hormones in children with chronic renal failure.
    Rauh W, Hund E, Sohl G, Rascher W, Mehls O, Schärer K.
    Kidney Int Suppl; 1983 Nov; 15():S27-33. PubMed ID: 6368949
    [Abstract] [Full Text] [Related]

  • 16. Regulations of plasma aldosterone in young hyperkalemic patients with stable chronic renal failure.
    Radó JP, Boer P.
    Endokrinologie; 1979 Apr; 73(2):173-85. PubMed ID: 467373
    [Abstract] [Full Text] [Related]

  • 17. [Effect of captopril on the plasma aldosterone response to metoclopramide in normal subjects].
    Zachariéva S, Koev D, Tcharaktchiev D, Moskov M, Andonova K.
    Ann Endocrinol (Paris); 1989 Apr; 50(3):233-6. PubMed ID: 2683976
    [Abstract] [Full Text] [Related]

  • 18. [The effect of dopaminergic antagonists on plasma aldosterone in normal subjects and patients with hypopituitarism].
    Shikuma R, Yoshimura M, Takashina R, Yamazaki H, Kambara S, Ijichi H.
    Nihon Naibunpi Gakkai Zasshi; 1984 Sep 20; 60(9):1041-5. PubMed ID: 6394371
    [Abstract] [Full Text] [Related]

  • 19. Effect of dopaminergic blockade on plasma aldosterone in acquired hypoaldosteronism.
    Krishna GG, Chusid P, Hoeldtke RD.
    Nephron; 1987 Sep 20; 47(3):184-9. PubMed ID: 3683686
    [Abstract] [Full Text] [Related]

  • 20. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man.
    Sowers JR, Sharp B, McCallum RW.
    J Clin Endocrinol Metab; 1982 Apr 20; 54(4):869-71. PubMed ID: 7037817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.